ProfoundBio is a US-based biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer.
Location: China, Jiangsu, Suzhou
Total raised: $112M
Investors 2
| Date | Name | Website |
| 15.02.2024 | Octagon Ca... | octagoninv... |
| 10.03.2023 | B Capital ... | bcapgroup.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.02.2024 | Series B | $112M | - |
Mentions in press and media 14
| Date | Title | Description | Source |
| 13.02.2024 | ProfoundBio Raises $112M in Series B Funding | ProfoundBio, a Seattle, WA-based clinical-stage biotechnology company developing novel antibody-drug... | finsmes.co... |
| 05.10.2023 | ProfoundBio to Participate in the Bank of America 2023 Healt... | SEATTLE, Oct. 5, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on... | en.prnasia... |
| 28.09.2023 | ProfoundBio Announces Upcoming Scientific Presentations at S... | SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused ... | en.prnasia... |
| 28.08.2023 | ProfoundBio to Participate in the 21st Annual Morgan Stanley... | SEATTLE, Aug. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused o... | en.prnasia... |
| 26.05.2023 | ProfoundBio Announces Further Advancement of Lead Programs -... | PRO1160 first patient dosed in the US China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S... | en.prnasia... |
| 24.03.2023 | ProfoundBio Highlights Broad Antitumor Activity in Preclinic... | WOODINVILLE, Wash. and SUZHOU, China, March 24, 2023 /PRNewswire/ -- ProfoundBio, a clinical stage b... | en.prnasia... |
| 03.01.2023 | ProfoundBio Announces Initiation of First-in-Human Trial for... | PRO1184 first-in human study initiated and first patients dosed PRO1160 first-in-human study cleared... | en.prnasia... |
| 03.08.2022 | ProfoundBio Receives FDA "Study May Proceed" Lette... | SUZHOU, China and WOODINVILLE, Wash., Aug. 3, 2022 /PRNewswire/ -- ProfoundBio, an oncology biothera... | en.prnasia... |
| 02.06.2022 | ProfoundBio Announces Completion of $70 Million Series A+ Fi... | - Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into preclinical d... | en.prnasia... |
| 09.03.2022 | ProfoundBio to Highlight Programs and Technology at AACR 202... | SEATTLE, Wash. and SUZHOU, China, March 9, 2022 /PRNewswire/ -- ProfoundBio announced that preclinic... | en.prnasia... |
Show more